Splink

About Splink

Splink Inc. is a Japanese health technology company founded in January 2017 by Yuki Aoyama. It operates in the brain healthcare field, developing medical AI solutions to address challenges related to an aging society, with a particular focus on dementia. Aoyama's background includes business development at Keyence Corporation and experience as an Entrepreneur in Residence (EiR) at a Silicon Valley venture capital firm.

The company provides comprehensive solutions spanning prevention, diagnosis, and post-onset support for central nervous system diseases like dementia. Splink's product portfolio includes a self-check cognitive function tool called the 'CQ test' and a Software as a Medical Device (SaMD) named 'Braineer'. Braineer is a brain image analysis program that assists physicians by quantifying and digitizing the degree of brain atrophy from MRI scans to support diagnosis. Another product, a brain checkup program, uses AI to measure the hippocampus to visualize age-related changes in the brain. These tools aim to enable more accurate and personalized diagnosis and treatment.

Splink's business model involves providing its software to medical institutions, as well as to pharmaceutical and medtech companies that can use it for managing large databases and for their data catalogs. The company targets challenges in the diagnostic process, such as dependency on physician experience, the limited availability of advanced tests like amyloid-PET scans, and the lack of continuous monitoring systems. Splink has been selected for several prominent programs, including J-Startup by the Ministry of Economy, Trade and Industry, and has received multiple grants from Japan's New Energy and Industrial Technology Development Organization (NEDO).